While an initial study reported an induction of bone metastasis with PARPi, being mainly mediated by PARP-2 in the myeloid lineage and less by PARP-2 in cancer cells, this study administered PARPi first for one week prior to the injection of cancer cells [119]. The gene discussed is PARP2; the disease is cancer.